Thermo Fisher Scientific Chk1 Polyclonal Antibody

Applications

Tested Dilution

Publications

Western Blot (WB)

1:500-1:1,000

-

Immunocytochemistry (ICC/IF)

1:1,500-1:50,000

-

ELISA (ELISA)

1:25,000-1:50,000

-

Immunoprecipitation (IP)

0.2-1 µL/mg of lysate

-

Product Specifications

Species Reactivity

Human

Host/Isotype

Rabbit / IgG

Class

Polyclonal

Type

Antibody

Immunogen

Recombinant Human Chk1 Protein (Met1-Thr476) if (typeof window.$mangular === undefined || !window.$mangular) { window.$mangular = {}; } $mangular.antigenJson = \[{targetFamily:Chk1,uniProtId:O14757-1,ncbiNodeId:9606,antigenRange:1-476,antigenLength:476,antigenImageFileName:PA5-80475_Chk1_O14757-1_Rabbit.svg,antigenImageFileNamePDP:PA5-80475_Chk1_O14757-1_Rabbit_PDP.jpeg,sortOrder:1}\]; $mangular.isB2BCMGT = false; $mangular.isEpitopesModalImageMultiSizeEnabled = true;

View immunogen .st0{fill:#FFFFFF;} .st1{fill:#1E8AE7;}

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

1.05 mg/mL

Purification

Protein A, Antigen affinity chromatography

Storage buffer

PBS, pH 7

Contains

no preservative

Storage conditions

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_2787788

Product Specific Information

This product is preservative free. It is recommended to add sodium azide to avoid contamination (final concentration 0.05%-0.1%).

This antibody has specificity for Human Chk1.

Target Information

CHEK1 (CHK1) is a serine/threonine protein kinase involved in preventing replication when DNA integrity is compromised. CHK1 is a key mediator in the DNA damage-induced checkpoint network. CHK1 is an evolutionarily conserved protein kinase that functions to ensure genomic integrity upon genotoxic stress. When the G2 or S checkpoint is abrogated by the inhibition of CHK1, p53-deficient cancer cells undergo mitotic catastrophe and eventually apoptosis, whereas normal cells are still arrested in the G1 phase. Thus, CHK1 inhibitors can preferentially potentiate the efficacy of DNA damaging agents in cancer cells, and Chk1 is an attractive therapeutic target for cancer treatment, especially since approximately 50% of all human cancers are p53-deficient.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.